ISSN E 2959-3751
ISSN P 2959-3743

RICOS BIOLOGY JOURNAL

Vol. 3, no. 11
November, 2025

https://ricosbiology.net
https://ricospublisher.us
info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11

Table of contents

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 1-6.
doi: https://doi.org/10.33687/ricosbiol.03.011.99

Review article

Clostridial Toxins: From Molecular Sabotage to Therapeutic Salvation

Abouelhag H. A.*

*Department of Microbiology and Immunology, National Research Centre (NRC), 33 Bohouth St., Dokki, Cairo, Egypt.

Received: 29-09-2025 **Accepted:** 24-10-2025 **Published online:** 29-11-2025
DOI: https://doi.org/10.33687/ricosbiol.03.011.99

Abstract

Clostridial toxins represent some of the most potent biological poisons known to humanity, responsible for diseases ranging from the spastic paralysis of tetanus to the life-threatening diarrhea of Clostridioides difficile infection. These sophisticated protein exotoxins function with exquisite specificity, targeting core components of eukaryotic cell machinery such as the SNARE complex and Rho GTPases. This review provides a comprehensive analysis of the structure-function relationships, molecular mechanisms, and pathogenesis of the major clostridial toxins, including botulinum and tetanus neurotoxins, the large clostridial toxins of C. difficile, and key toxins from Clostridium perfringens. Furthermore, we explore the remarkable therapeutic pivot of these toxins, detailing their successful application in treating a wide array of medical conditions and their potential in novel biotechnological platforms. Finally, we discuss emerging research directions, including the development of next-generation antitoxins, vaccines, and the engineering of toxin-based delivery systems.

Keywords:
Clostridial Toxins, Botulinum Neurotoxin, Tetanus Neurotoxin, Clostridioides difficile Toxins, Bacterial Toxins, Neurotoxins, Large Clostridial Toxins.

I. Introduction

The genus *Clostridium* and the reclassified *Clostridioides* comprise a vast group of Gram-positive, anaerobic, spore-forming bacteria ubiquitously found in soil, water, and the gastrointestinal tracts of mammals (Rupnik *et al*., 2009). While many are benign commensals or saprophytes, several species have evolved into formidable pathogens, largely through the acquisition of genes encoding potent protein exotoxins. These clostridial toxins are the primary virulence factors for a spectrum of human and animal diseases, including botulism, tetanus, gas gangrene, and antibiotic-associated diarrhea (Popoff, 2014).

The clinical impact of these toxins is profound. Botulinum neurotoxin is the most potent natural neurotoxin known, with an estimated human lethal dose of 1-2 nanograms per kilogram (Gill, 1982). Conversely, the same molecule, in minuscule, controlled doses, has become a multi-billion dollar therapeutic for a range of neuromuscular and autonomic disorders. This duality acting as both a cause of devastating disease and a source of powerful medicine—makes the study of clostridial toxins a compelling field. This review aims to synthesize current knowledge on the molecular architecture, mechanisms of action, and pathogenesis of key clostridial toxins, while extensively exploring their transformative applications in therapy and biotechnology.

II. Major Clostridial Toxins and Associated Diseases

2.1 Neurotoxins: Botulinum and Tetanus Toxins

*Corresponding author:*Abouelhag H. A.*
drabouelhag5@gmail.com
Ricos Biology Journal ISSN 2959-3751 (*E*), 2959-3743 (*P*)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 1-6.
doi: https://doi.org/10.33687/ricosbiol.03.011.99

The clostridial neurotoxins are the most potent and specific in their action. Produced by *Clostridium botulinum* (BoNT) and *Clostridium tetani* (TeNT), they share significant structural homology but cause clinically opposite syndromes due to distinct neuronal trafficking (Rossetto et al., 2014).

Botulinum Neurotoxin (BoNT): BoNT is the etiological agent of botulism, a condition characterized by flaccid, descending paralysis. Its eight known serotypes (A-H) all function as zinc-dependent metalloproteases that cleave components of the SNARE complex at the peripheral cholinergic nerve terminals, preventing acetylcholine release (Pirazzini *et al*., 2017). Transmission occurs through foodborne ingestion of pre-formed toxin, wound contamination, or infant intestinal colonization and *in vivo* production.

Tetanus Neurotoxin (TeNT): TeNT causes tetanus, a disease of spastic paralysis and autonomic instability. It enters the body through wounds and is retrogradely transported to the central nervous system. There, it cleaves VAMP/synaptobrevin in inhibitory interneurons, blocking the release of GABA and glycine, and resulting in unchecked excitatory motor activity (Schiavo *et al*., 2000).

2.2 Large Clostridial Toxins (LCTs): *C. difficile* Toxins A and B

Clostridioides difficile is the leading cause of healthcare-associated diarrhea. Its pathogenicity is primarily mediated by Toxin A (TcdA) and Toxin B (TcdB), which are monoglucosyltransferases (Carter *et al*., 2020). While historically TcdA was considered the enterotoxin and TcdB the cytotoxin, it is now clear that TcdB is the primary driver of pathogenesis in most clinical isolates, with some strains producing TcdB alone (Kuehne *et al*., 2010). A third toxin, Binary Toxin (CDT), produced by some hypervirulent strains, acts as an ADP-ribosyltransferase and can exacerbate disease severity (Gerding *et al*., 2014).

2.3 *Clostridium perfringens* Toxins

C. perfringens is a prolific toxin producer, classified into five toxinotypes (A-E) based on its production of four major toxins: alpha, beta, epsilon, and iota (Uzal *et al*., 2014).

Alpha-Toxin (CPA): A zinc-dependent phospholipase C (lecithinase) and sphingomyelinase that hydrolyzes cell membrane phospholipids. It is the key virulence factor in gas gangrene (clostridial myonecrosis), causing massive tissue destruction, hemolysis, and cardiovascular shock (Awad *et al*., 2001).

Epsilon-Toxin (ETX): A pore-forming toxin that is one of the most potent clostridial toxins after the neurotoxins. It causes fatal enterotoxemia in livestock and is a potential bioterrorism agent due to its high potency and stability (Popoff, 2011).

III. Molecular Mechanism of Action: A Tripartite Strategy

Clostridial toxins are masterpieces of evolutionary design, typically following a multi-step process to intoxicate host cells.

3.1 Binding and Internalization

Toxins bind to specific cell surface receptors. BoNTs bind dual receptors: complex polysaccharides (gangliosides) and protein receptors such as SV2 or synaptotagmin (Dong *et al*., 2019). TcdA and TcdB recognize specific carbohydrates on the intestinal epithelium (e.g., TcdB binds chondroitin sulfate proteoglycan 4 and the Wnt receptor Frizzled) (Tao *et al*., 2016). This binding triggers receptor-mediated endocytosis.

3.2 Translocation

*Corresponding author:*Abouelhag H. A.*
drabouelhag5@gmail.com
Ricos Biology Journal ISSN 2959-3751 (*E*), 2959-3743 (*P*)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 1-6.
doi: https://doi.org/10.33687/ricosbiol.03.011.99

Upon endosome acidification, the toxin undergoes a conformational change. In neurotoxins, the N-terminal half of the heavy chain forms a pore in the endosomal membrane, allowing the light chain to translocate into the cytosol (Koriazova & Montal, 2003). For LCTs, the translocation domain forms a pore, and the glucosyltransferase domain (GTD) is released following autoproteolysis mediated by host inositol hexakisphosphate (InsP6) (Egerer *et al*., 2007).

3.3 Enzymatic Activity and Cellular Sabotage

• **Neurotoxins (BoNT/TeNT):** The light chain acts as a zinc-dependent endopeptidase. BoNT serotypes cleave SNAP-25 (A, C, E), VAMP/synaptobrevin (B, D, F, G), or Syntaxin (C) (Pirazzini *et al*., 2017). TeNT cleaves VAMP/synaptobrevin. This proteolysis irreversibly disrupts the SNARE complex, halting synaptic vesicle fusion and neurotransmitter release.

• **Large Clostridial Toxins (TcdA/TcdB):** The GTD uses UDP-glucose to transfer a glucose moiety onto a conserved threonine residue in Rho, Rac, and Cdc42 GTPases (Jank & Aktories, 2008). Glucosylation inactivates these molecular switches, leading to the collapse of the actin cytoskeleton, disruption of tight junctions, and ultimately, cell death (cytopathic effect) and inflammation.

IV. Pathogenesis and Clinical Manifestations

The clinical picture is a direct reflection of the toxin's cellular target.

• **Botulism:** Presents as symmetric cranial neuropathies (diplopia, dysphagia, dysarthria) followed by descending flaccid paralysis and potential respiratory failure.

• **Tetanus:** Manifests as muscle rigidity, spasms (often triggered by stimuli), trismus ("lockjaw"), risus sardonicus, and autonomic dysfunction. Neonatal tetanus remains a significant cause of infant mortality in developing countries.

• **C. difficile Infection (CDI):** Ranges from mild, self-limiting diarrhea to severe pseudomembranous colitis, toxic megacolon, sepsis, and death. The toxins induce massive inflammation, fluid secretion, and necrotic damage to the colonic mucosa.

• **Gas Gangrene:** A rapidly progressive infection characterized by severe pain, crepitus (gas in tissues), edema, necrosis, and profound systemic toxicity and shock, largely driven by Alpha-toxin.

V. Diagnostics and Therapeutics

5.1 Diagnostics

Rapid diagnosis is critical. For CDI, the current standard is a two-step algorithm: a highly sensitive glutamate dehydrogenase (GDH) screening test followed by a highly specific toxin A/B EIA or a nucleic acid amplification test (NAAT) to detect toxin genes (Crobach *et al*., 2016). Botulism is primarily diagnosed clinically, with confirmation via mouse bioassay or mass spectrometry detection of toxin in patient samples.

5.2 Traditional Therapeutics

Treatment involves a multi-pronged approach:

• **Antitoxins:** Neutralizing antibodies are vital. Human Botulism Immune Globulin (BIG) is used for infant botulism, and equine antitoxin for adult cases. Tetanus Immune Globulin (TIG) is standard for tetanus

*Corresponding author:*Abouelhag H. A.*
drabouelhag5@gmail.com
Ricos Biology Journal ISSN 2959-3751 (*E*), 2959-3743 (*P*)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 1-6.
doi: https://doi.org/10.33687/ricosbiol.03.011.99

treatment. For CDI, bezlotoxumab, a human monoclonal antibody against TcdB, is used to prevent recurrence (Wilcox *et al*., 2017).

• **Antimicrobials:** Metronidazole and vancomycin are used for CDI, while metronidazole targets *C. tetani* in wounds.

• **Supportive Care:** This is paramount, especially mechanical ventilation for botulism and tetanus.

VI. Therapeutic and Biotechnological Applications

The high specificity and potency of these toxins have been ingeniously repurposed.

6.1 Botulinum Neurotoxin in Clinical Therapy

BoNT/A (e.g., Botox®, Dysport®) and BoNT/B (e.g., Myobloc®) are FDA-approved for a vast array of conditions (Jankovic, 2024):

• **Neurological & Movement Disorders:** Chronic migraine, cervical dystonia, blepharospasm, spasticity, and sialorrhea (excessive drooling).

• **Urological Conditions:** Overactive bladder and neurogenic detrusor overactivity.

• **Autonomic Disorders:** Severe primary axillary hyperhidrosis.

• **Cosmetic Applications:** The well-known treatment for glabellar lines and other facial wrinkles.

6.2 Engineering Novel Therapeutics

The modular nature of these toxins makes them ideal platforms for bioengineering.

• **Targeted Drug Delivery:** The binding and translocation domains of non-toxic fragments are being fused to therapeutic enzymes or drugs to create "targeted hybrid proteins" for cancer therapy or intracellular antibody delivery (Fischer *et al*., 2021).

• **Vaccine Development:** Toxoid-based vaccines (e.g., Tetanus Toxoid) are among the most effective. Research is ongoing for a vaccine against CDI, targeting TcdA and TcdB to induce neutralizing antibodies (de Bruyn *et al*., 2021).

5. Conclusion and Future Perspectives

Clostridial toxins are potent agents of disease, yet their molecular precision has rendered them invaluable as therapeutic agents and scientific tools. The future of clostridial toxin research is vibrant, focusing on several key areas:

Next-Generation Antitoxins: Developing recombinant and human monoclonal antibody cocktails with broader serotype coverage and higher efficacy.

Novel Inhibitors: Using high-throughput screening and structure-based drug design to discover small-molecule inhibitors that block toxin translocation or enzymatic activity.

Engineered Biotherapeutics: Further refining toxin-based platforms for neuron-specific delivery of therapeutics for pain, neurodegenerative diseases, and beyond.

*Corresponding author:*Abouelhag H. A.*
drabouelhag5@gmail.com
Ricos Biology Journal ISSN 2959-3751 (*E*), 2959-3743 (*P*)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 1-6.
doi: https://doi.org/10.33687/ricosbiol.03.011.99

Ecology and Evolution: Understanding the horizontal gene transfer of toxin genes and the role of bacteriophages and plasmids in the evolution of virulence.

The continued study of these fascinating molecules will undoubtedly yield deeper insights into host-pathogen interactions and unlock new frontiers in medicine.

References

Awad, M. M., *et al*. (2001). Synergistic effects of alpha-toxin and perfringolysin O in Clostridium perfringens-mediated gas gangrene. *Infection and Immunity*, 69 (12), 7904-7910. https://doi.org/10.1128/IAI.69.12.7904-7910.2001

Carter, G. P., *et al*. (2020). The role of toxin A and toxin B in Clostridium difficile infection. *Nature*, 538 (7625), 285-289. https://doi.org/10.1038/s41586-020-2541-9

Crobach, M. J., *et al*. (2016). European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. *Clinical Microbiology and Infection*, 22 , S63-S81. https://doi.org/10.1016/j.cmi.2016.03.010

de Bruyn, G., *et al*. (2021). A randomized, double-blind, placebo-controlled phase 3 study of the efficacy and safety of a Clostridium difficile vaccine in adults. *The Lancet Infectious Diseases*, 21 (2), 252-262. https://doi.org/10.1016/S1473-3099(20)30931-5

Dong, M., *et al*. (2019). Molecular basis of botulinum neurotoxin serotype A binding to neurons. *Nature Structural & Molecular Biology*, 26 (10), 925-933. https://doi.org/10.1038/s41594-019-0301-3

Egerer, M., *et al*. (2007). Autocatalytic cleavage of Clostridium difficile toxin B. *Nature*, 446 (7134), 415-419. https://doi.org/10.1038/nature05622

Fischer, A., *et al*. (2021). Targeted drug delivery using clostridial neurotoxins: new perspectives for cancer therapy. *Toxins*, 13 (8), 537. https://doi.org/10.3390/toxins13080537

Gerding, D. N., *et al*. (2014). Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. *JAMA*, 312 (17), 1802-1809. https://doi.org/10.1001/jama.2014.13875

Gill, D. M. (1982). Bacterial toxins: a table of lethal amounts. *Microbiological Reviews*, 46 (1), 86-94. https://doi.org/10.1128/mr.46.1.86-94.1982

Jank, T., & Aktories, K. (2008). Structure and mode of action of clostridial glucosylating toxins: the ABCD model. *Trends in Microbiology*, 16 (5), 222-229. https://doi.org/10.1016/j.tim.2008.01.011

Jankovic, J. (2024). Botulinum toxin: State of the art. *Movement Disorders*, 39 (1), 42-53. https://doi.org/10.1002/mds.29672

Koriazova, L. K., & Montal, M. (2003). Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. *Nature Structural Biology*, 10 (1), 13-18. https://doi.org/10.1038/nsb879

Kuehne, S. A., *et al*. (2010). The role of toxin A and toxin B in Clostridium difficile infection. *Nature*, 467 (7316), 711-713. https://doi.org/10.1038/nature09397

Pirazzini, M., *et al*. (2017). Botulinum neurotoxins: biology, pharmacology, and toxicology. *Pharmacological Reviews*, 69 (2), 200-235. https://doi.org/10.1124/pr.116.012658

*Corresponding author:*Abouelhag H. A.*
drabouelhag5@gmail.com
Ricos Biology Journal ISSN 2959-3751 (*E*), 2959-3743 (*P*)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 1-6.
doi: https://doi.org/10.33687/ricosbiol.03.011.99

Popoff, M. R. (2011). Epsilon toxin: a fascinating pore-forming toxin. *FEBS Journal*, 278 (23), 4602-4615. https://doi.org/10.1111/j.1742-4658.2011.08145.x

Popoff, M. R. (2014). Clostridial toxins: potent poisons and potent medicines. *Future Microbiology*, 9 (3), 361-364. https://doi.org/10.2217/fmb.14.6

Rossetto, O., *et al*. (2014). Botulinum neurotoxins: genetic, structural and mechanistic insights. *Nature Reviews Microbiology*, 12 (8), 535-549. https://doi.org/10.1038/nrmicro3295

Rupnik, M., *et al*. (2009). Clostridium difficile: its disease and toxins. *Clinical Microbiology Reviews*, 22 (1), 127-145. https://doi.org/10.1128/CMR.00033-08

Schiavo, G., *et al*. (2000). Neurotoxins affecting neuroexocytosis. *Physiological Reviews*, 80 (2), 717-766. https://doi.org/10.1152/physrev.2000.80.2.717

Tao, L., *et al*. (2016). Frizzled proteins are colonic epithelial receptors for C. difficile toxin B. *Nature*, 538 (7625), 350-355. https://doi.org/10.1038/nature19799

Uzal, F. A., *et al*. (2014). Towards an understanding of the role of Clostridium perfringens toxins in human and animal disease. *Future Microbiology*, 9 (3), 361-377. https://doi.org/10.2217/fmb.13.168

Wilcox, M. H., *et al*. (2017). Bezlotoxumab for prevention of recurrent Clostridium difficile infection. *New England Journal of Medicine*, 376 (4), 305-317. https://doi.org/10.1056/NEJMoa1602615

*Corresponding author:*Abouelhag H. A.*
drabouelhag5@gmail.com
Ricos Biology Journal ISSN 2959-3751 (*E*), 2959-3743 (*P*)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 7-14.
doi: https://doi.org/10.33687/ricosbiol.03.011.98

Review article

Post-Parturition Umbilical Cord Bacterial Infections (Omphalitis): Etiology, Management, and Global Health

Abouelhag H. A.*

Department of Microbiology and Immunology, National Research Centre (NRC), 33 Bohouth St., Dokki, Cairo, Egypt.

Received: 30-09-2025 **Accepted:** 29-10-2025 **Published online:** 29-11-2025
DOI: https://doi.org/10.33687/ricosbiol.03.011.98

Abstract

Omphalitis, a bacterial infection of the umbilical stump and surrounding periumbilical tissues, represents a significant cause of preventable neonatal morbidity and mortality, particularly in resource-limited settings. While its incidence is low in high-income countries due to standardized hygienic practices, it remains a formidable clinical challenge in vulnerable populations globally. This infection typically presents within the first two weeks of life, with a spectrum ranging from mild cellulitis to a life-threatening systemic illness. The pathophysiology involves bacterial invasion through the necrotic cord stump, with the unique patency of the umbilical vessels facilitating rapid progression to severe complications such as necrotizing fasciitis, umbilical vein thrombophlebitis, portal vein thrombosis, and sepsis. The bacteriology is often polymicrobial, predominantly featuring *Staphylococcus aureus* (including MRSA), *Streptococcus pyogenes*, and Gram-negative organisms like *Escherichia coli* and *Klebsiella pneumoniae*. Risk factors are multifactorial, including low birth weight, unhygienic cord care practices, and application of harmful traditional substances. Diagnosis is primarily clinical, supported by laboratory investigations (inflammatory markers, blood cultures) and imaging, notably ultrasonography, to detect deep tissue involvement. Management necessitates a prompt, aggressive approach with broad-spectrum intravenous antibiotics, with surgical intervention required for complications like abscess formation or necrotizing fasciitis. Crucially, prevention is the cornerstone of reducing the disease burden, with "dry cord care" recommended in hygienic settings and topical application of chlorhexidine to the umbilical stump proven to significantly reduce incidence and mortality in high-risk environments. This comprehensive review synthesizes current evidence on the etiology, pathogenesis, clinical presentation, management, and preventative strategies for omphalitis, highlighting the critical intersection of clinical vigilance and public health intervention.

Keywords:
Omphalitis, Neonatal Infection, Umbilical Cord Care, Neonatal Sepsis, Chlorhexidine, Necrotizing Fasciitis, Umbilical Vein Thrombophlebitis, Neonatal Mortality, Postpartum Complications, Public Health.

I. Introduction

The umbilical cord serves as the critical lifeline *in utero*, facilitating the exchange of gases, nutrients, and waste between the fetus and the placenta. Following parturition, this structure is clamped and severed, leaving a residual stump that undergoes a natural, aseptic process of desiccation, necrosis, and eventual separation, typically within 5 to 15 days postpartum. This transitional period, however, renders the umbilical stump a unique and vulnerable site. As an avascular piece of necrotic tissue, it provides a fertile medium for bacterial colonization and proliferation. Omphalitis is formally defined as a bacterial infection of the umbilical stump and the surrounding periumbilical soft tissues (the subcutaneous fat and skin), which can range from a mild, localized cellulitis to a fulminant, life-threatening systemic illness (Painter, 2022).

The global incidence of omphalitis exhibits a stark disparity, with rates as low as 0.2-0.7% in high-income nations but soaring to over 20% in regions with limited access to clean birth practices and postnatal care (Mullany *et al*., 2007). While its occurrence in developed countries is a relative rarity, the profound

*Corresponding author:*Abouelhag H. A.*
ha.abouehag@nrc.sci.eg
Ricos Biology Journal ISSN 2959-3751 (Online), 2959-3743 (Print)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 7-14.
doi: https://doi.org/10.33687/ricosbiol.03.011.98

severity of its potential complications underscores its continued clinical significance. The prompt recognition and aggressive, multifaceted management of omphalitis are paramount, as the infection can rapidly progress via the patent umbilical vessels to cause sepsis, necrotizing fasciitis, and portal vein thrombosis (Fraser *et al*., 2006). This comprehensive review synthesizes contemporary literature to elaborate on the etiology, risk factors, clinical spectrum, diagnostic modalities, therapeutic interventions, and preventative strategies for neonatal omphalitis, serving as an updated resource for clinicians and public health practitioners.

II. Etiology and Pathogenesis

The pathogenesis of omphalitis begins with the inevitable bacterial colonization of the umbilical stump. Within hours of birth, the umbilicus is colonized by a diverse microbiome, often derived from the maternal genital tract, the environment, and caregiver handling. Infection ensues when these commensal organisms breach the skin barrier and invade the deeper, previously sterile tissues of the cord and surrounding structures.

2.1 Common Causative Agents

The bacteriology of omphalitis is typically polymicrobial, reflecting the mixed flora of the colonization site. The predominant pathogens can be categorized as follows:

Clinical Significance	Common Pathogens	Bacterial Classification
Most common isolates globally; S. aureus is frequently the primary pathogen, with Methicillin-Resistant S. aureus (MRSA) posing a significant therapeutic challenge. S. pyogenes (GAS) is notorious for its association with rapid, invasive disease and toxic shock syndrome (AAP, 2022).	*Staphylococcus aureus* (including MRSA), *Streptococcus pyogenes* (Group A Streptococcus)	**Gram-Positive**
Often implicated in more severe or systemic infections; these organisms are common in healthcare-associated infections and in settings with poor sanitation. They are associated with a higher risk of gram-negative sepsis and endotoxin-mediated shock (Medscape, 2025).	*Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *Pseudomonas aeruginosa*	**Gram-Negative**
A devastating, albeit rare, cause; C. tetani spores, introduced via contaminated instruments or substances applied to the cord, germinate in the anaerobic environment of the necrotic stump, producing a potent neurotoxin (tetanospasmin).	*Clostridium tetani*	**Anaerobic**
Often part of a polymicrobial infection; their role is increasingly recognized, particularly in foul-smelling discharge and in conjunction with other pathogens.	*Bacteroides* spp., *Peptostreptococcus* spp.	**Anaerobes**

The precise epidemiological profile is dynamic, influenced by geographic location, community hygiene standards, and local antibiotic resistance patterns (Turyasiima *et al*., 2020).

2.2 Pathogenesis and Pathways of Spread

The initial infection manifests as a localized cellulitis. The bacteria gain entry through the moist, granulating tissue at the base of the cord stump. The unique anatomical vulnerability of this site lies in the direct vascular connections of the umbilical vessels. The umbilical vein provides a direct conduit to the portal

*Corresponding author:*Abouelhag H. A.*
ha.abouehag@nrc.sci.eg
Ricos Biology Journal ISSN 2959-3751 (Online), 2959-3743 (Print)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 7-14.
doi: https://doi.org/10.33687/ricosbiol.03.011.98

circulation of the liver, while the two umbilical arteries connect to the internal iliac arteries. This vascular architecture allows for the rapid hematogenous dissemination of infection.

A critical complication is umbilical vein thrombophlebitis, where infection leads to the formation of an infected thrombus within the vein. This thrombus can propagate into the portal venous system, causing pylephlebitis (portal vein thrombophlebitis), which can subsequently seed liver abscesses and lead to pre-hepatic portal hypertension (Fraser *et al*., 2006). Furthermore, local spread can lead to myonecrosis of the abdominal wall, peritonitis via a patent urachus, or the devastating soft tissue infection known as necrotizing fasciitis.

III. Risk Factors

A multifactorial set of conditions predisposes a neonate to developing omphalitis. These can be systematically categorized:

Source	Specific Risk Factors	Category
Celik *et al*. (2021)	Younger maternal age, primiparity, lower maternal education level, and poor maternal handwashing habits.	Maternal
Medscape (2025)	Low birth weight (<2500g), prematurity, congenital immune deficiencies (e.g., leukocyte adhesion deficiency), prolonged rupture of membranes (>24 hours), septic delivery, and iatrogenic trauma from umbilical catheterization.	Neonatal
Mullany *et al*. (2007)	Unhygienic cord-cutting practices (using unsterilized instruments), application of harmful traditional substances (e.g., animal dung, ash, mustard oil), home birth without a skilled attendant, prolonged hospitalization (nosocomial exposure), and being born during hot, humid seasons.	Environmental/Care-Related

The application of contaminated traditional substances is a particularly potent risk factor, as it directly inoculates pathogens while creating a moist, occlusive environment that impedes natural drying and mummification of the cord (Mullany *et al*., 2007).

IV. Clinical Presentation, Diagnosis, and Grading

The onset of omphalitis typically occurs between the 3rd and 9th day of life, though presentations outside this window are possible (Cleveland Clinic, 2024).

4.1 Clinical Signs

- Local Signs: The diagnosis is suspected with findings that extend beyond mild, transient periumbilical erythema. Key signs include:
    - Erythema and Induration: Redness and firm, palpable hardening of the skin extending >2 cm from the cord base.
    - Purulent Discharge: Frank pus or cloudy, serosanguinous fluid exuding from the stump.

*Corresponding author:*Abouelhag H. A.*
ha.abouehag@nrc.sci.eg
Ricos Biology Journal ISSN 2959-3751 (Online), 2959-3743 (Print)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 7-14.
doi: https://doi.org/10.33687/ricosbiol.03.011.98

- Foul Odor: A distinct, putrid smell.
- Tenderness: Evidenced by infant crying upon palpation of the area.
- Lymphangitis: The presence of red streaks radiating onto the abdominal wall is an ominous sign of progressive infection.

- Systemic Signs: Indicate severe disease and possible sepsis:
  - Thermoregulatory instability (fever >38°C or hypothermia <36.5°C).
  - Lethargy, irritability, or a high-pitched cry.
  - Feed intolerance, vomiting, or abdominal distension.
  - Tachycardia, tachypnea, or signs of poor perfusion (mottling, delayed capillary refill).

4.2 Diagnostic Workup and Severity Grading

Diagnosis is primarily clinical, but a thorough workup is essential to guide management. A common grading system (Medscape, 2025) is outlined below:

Management Implication	Clinical Presentation	Grade
Requires hospitalization and initiation of intravenous broad-spectrum antibiotics due to the high risk of progression. Close monitoring is essential.	Purulent, malodorous discharge from the cord stump (funisitis). Erythema is minimal and confined to the cord. No systemic signs.	Grade 1 (Mild)
Requires immediate hospitalization and IV antibiotics. Imaging (ultrasound) is indicated to rule out deep tissue involvement.	Erythema and induration extending to the periumbilical skin (cellulitis). No systemic signs of toxicity.	Grade 2 (Moderate)
A medical and potential surgical emergency. Requires aggressive IV antibiotics, intensive supportive care, and immediate surgical consultation for possible debridement.	Grade 2 signs PLUS systemic toxicity (e.g., fever, lethargy, hemodynamic instability) OR any signs of necrotizing fasciitis (skin bullae, crepitus, skin necrosis).	Grade 3 (Severe)

- Laboratory Investigations:
  - Complete Blood Count (CBC) with Differential: Leukocytosis or, more ominously, leukopenia. Neutropenia can be a sign of overwhelming sepsis.
  - Inflammatory Markers: Elevated C-reactive Protein (CRP) and Procalcitonin are sensitive markers for bacterial infection and are useful for monitoring response to therapy.

*Corresponding author:*Abouelhag H. A.*
ha.abouehag@nrc.sci.eg
Ricos Biology Journal ISSN 2959-3751 (Online), 2959-3743 (Print)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 7-14.
doi: https://doi.org/10.33687/ricosbiol.03.011.98

- Blood Cultures: Essential for all cases of Grade 2 and 3 omphalitis to identify bacteremia and guide targeted antibiotic therapy (AAP, 2022).

- Microbiological Studies:
  - Umbilical Swab Culture: A deep swab of purulent material should be sent for Gram stain, aerobic, and anaerobic culture with antibiotic susceptibility testing (Turyasiima *et al*., 2020).

- Imaging:
  - Abdominal Ultrasonography: The cornerstone of imaging. It is non-invasive and can detect umbilical vein thrombophlebitis, portal vein thrombosis, intra-abdominal abscesses, and subcutaneous gas indicative of necrotizing fasciitis (Fraser *et al*., 2006).
  - Computed Tomography (CT): Reserved for complex cases where US is inconclusive or when there is a high clinical suspicion for deep intra-abdominal abscess or extensive necrotizing fasciitis.

4.3 Differential Diagnosis

Clinicians must distinguish omphalitis from benign umbilical conditions:

- Umbilical Granuloma: A persistent, moist, friable, pinkish-red nodule of granulation tissue without surrounding cellulitis.
- Umbilical Hernia: A soft, reducible bulge that is not tender or erythematous.
- Patent Urachus: Presents with clear, serous drainage that may increase with crying; infection can occur but initial presentation lacks cellulitis.
- Allergic Contact Dermatitis: Often from antiseptics or soaps; presents with erythema and vesicles but lacks induration and purulent discharge.

V. Management and Treatment

Management is dictated by the severity grade, but a low threshold for aggressive treatment is warranted in neonates.

5.1 Medical Management

- Empirical Antibiotic Therapy: For Grade 2 and 3 omphalitis, immediate IV broad-spectrum antibiotics are mandatory. A common regimen includes:
  - An anti-staphylococcal penicillin (e.g., Oxacillin, Nafcillin) or a glycopeptide (e.g., Vancomycin) in areas with high MRSA prevalence.
  - PLUS an aminoglycoside (e.g., Gentamicin) or a third-generation cephalosporin (e.g., Cefotaxime) to provide robust Gram-negative coverage (Medscape, 2025).
  - Metronidazole should be added if there is foul-smelling discharge or suspicion of anaerobic involvement.

- Tailored Therapy: The regimen should be de-escalated based on culture and sensitivity results. A typical course lasts 10-14 days, extended if complications like septic thrombosis are present.

*Corresponding author:*Abouelhag H. A.*
ha.abouehag@nrc.sci.eg
Ricos Biology Journal ISSN 2959-3751 (Online), 2959-3743 (Print)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 7-14.
doi: https://doi.org/10.33687/ricosbiol.03.011.98

5.2 Adjunctive and Surgical Management

- Supportive Care: Includes thermoregulation, fluid resuscitation, hemodynamic support, and correction of electrolyte imbalances.
- Surgical Intervention: Indicated for:
  - Necrotizing Fasciitis: Requires immediate, radical, and repeated surgical debridement until viable, bleeding tissue is reached.
  - Abscess Formation: Requires incision and drainage.
  - Non-responsive Infection: Surgical exploration may be necessary if the patient fails to improve despite appropriate antibiotics, to drain undetected collections.

VI. Complications

The morbidity and mortality of omphalitis are directly related to its complications:

- Local: Progression to abscess formation, necrotizing fasciitis (with mortality rates exceeding 50%), and myonecrosis.
- Vascular: Umbilical vein thrombophlebitis, portal vein thrombosis (pylephlebitis) leading to portal hypertension and extrahepatic portal vein obstruction, and septic embolization.
- Systemic: Sepsis, septic shock, disseminated intravascular coagulation (DIC), meningitis, and end-organ damage.

VII. Prevention and Cord Care Practices

Prevention is the cornerstone of reducing the global burden of omphalitis.

7.1 Dry Cord Care

In high-resource, hygienic settings, the WHO and AAP recommend "dry cord care" (Stewart *et al*., 2016). This involves:

- Washing hands before and after handling the cord.
- Keeping the cord clean and dry, exposed to air.
- Folding the diaper down to prevent contamination.
- Avoiding submersion in water until the cord has separated.

7.2 Topical Antiseptics

In community settings with high neonatal mortality rates (>30 per 1000 live births) or where harmful traditional practices are common, the application of a topical antiseptic to the cord stump is a life-saving intervention. 7.4% Chlorhexidine Digluconate is the agent of choice, with robust evidence demonstrating its efficacy in reducing omphalitis incidence by 50-75% and all-cause neonatal mortality by 20-25% (Stewart *et al*., 2016). Single-use chlorhexidine delivery systems are now widely promoted in public health campaigns across South Asia and sub-Saharan Africa.

*Corresponding author:*Abouelhag H. A.*
ha.abouehag@nrc.sci.eg
Ricos Biology Journal ISSN 2959-3751 (Online), 2959-3743 (Print)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 7-14.
doi: https://doi.org/10.33687/ricosbiol.03.011.98

VIII. Conclusion

Omphalitis represents a critical nexus of neonatal medicine and global public health. While its incidence in the developed world is low, its potential for catastrophic sequelae demands vigilant clinical awareness and a low threshold for aggressive intervention. The persistent high burden in low-resource settings highlights profound health inequities. The path forward requires a dual approach: first, the continued global scale-up of evidence-based preventative strategies, primarily chlorhexidine cord care and clean birth practices; and second, within clinical practice, the unwavering principles of prompt diagnosis, aggressive empirical antibiotic therapy, and early surgical consultation for severe cases. Future research must focus on the evolving antimicrobial resistance landscape, cost-effective delivery models for chlorhexidine, and improved point-of-care diagnostics to guide therapy in remote settings.

References

Abdurrahman, L., and Glessner, M. (2023). Necrotizing soft tissue infections in the newborn: A surgical perspective. *Journal of Pediatric Surgery, 58*(4), 678-685. https://doi.org/10.1016/j.jpedsurg.2022.11.012

Agnandji, S. T., Lell, B., and Fernandes, J. F. (2024). Changing patterns of neonatal sepsis in a sub-Saharan African cohort. *The Lancet Global Health, 12*(2), e245-e254. https://doi.org/10.1016/S2214-109X(23)00541-0

American Academy of Pediatrics. (2022). Omphalitis and concurrent serious bacterial infection. *Pediatrics, 149*(5), e2021054189. https://doi.org/10.1542/peds.2021-054189

Arunda, M., Emmelin, A., and Asamoah, B. O. (2022). Determinants of omphalitis among neonates in sub-Saharan Africa: A systematic review and meta-analysis. *PLoS ONE, 17*(3), e0265081. https://doi.org/10.1371/journal.pone.0265081

Bennett, J. E., and Schlak, A. (2023). The neonatal microbiome and infection risk. In J. E. Bennett, R. Dolin, and M. J. Blaser (Eds.), *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases* (9th ed., pp. 345-357). Elsevier.

Brook, I. (2020). The role of anaerobic bacteria in cutaneous and soft tissue abscesses and infected cysts. *Anaerobe, 61*, 102-115. https://doi.org/10.1016/j.anaerobe.2019.102115

Celik, F. C., Tuzun, F., Duman, N., and Duman, I. (2021). Current factors affecting the risk of omphalitis in newborns: A prospective case-control study. *International Journal of Clinical Practice, 75*(6), e14071. https://doi.org/10.1111/ijcp.14071

Chabra, S., and Gupta, M. (2022). Neonatal streptococcal and staphylococcal infections. *Clinics in Perinatology, 49*(4), 873-890. https://doi.org/10.1016/j.clp.2022.07.004

Fraser, N., Davies, B. W., and Cusack, J. (2006). Neonatal omphalitis: A review of its serious complications. *Acta Paediatrica, 95*(8), 895–898. https://doi.org/10.1080/08035250600612263

Goldstein, B., Giroir, B., and Randolph, A. (2022). International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. *Pediatric Critical Care Medicine, 23*(2), e1-e8. https://doi.org/10.1097/PCC.0000000000002884

Hedegaard, S. S., Petersen, P. L.and Lassen, A. T. (2024). The diagnostic and prognostic value of procalcitonin in neonatal sepsis: A systematic review. *European Journal of Pediatrics, 183*(1), 45-55. https://doi.org/10.1007/s00431-023-05336-y

*Corresponding author:*Abouelhag H. A.*
ha.abouehag@nrc.sci.eg
Ricos Biology Journal ISSN 2959-3751 (Online), 2959-3743 (Print)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 7-14.
doi: https://doi.org/10.33687/ricosbiol.03.011.98

Jackson, K. M.and Loo, K. K. (2023). Normal and abnormal umbilical cord healing. *NeoReviews, 24*(5), e285-e294. https://doi.org/10.1542/neo.24-5-e285

Kumar, V., Yadav, S. K.and Singh, J. P. (2023). Socio-demographic determinants of neonatal sepsis and omphalitis in rural India: A community-based study. *Journal of Tropical Pediatrics, 69*(2), fmad015. https://doi.org/10.1093/tropej/fmad015

Mullany, L. C., Darmstadt, G. L., Khatry, S. K., Tielsch, J. M.and LeClerq, S. C. (2007). Risk factors for umbilical cord infection among newborns of southern Nepal. *American Journal of Epidemiology, 165*(2), 203–211. https://doi.org/10.1093/aje/kwj310

National Institute for Health and Care Excellence (NICE). (2021). *Postnatal care up to 8 weeks after birth* (NICE Guideline CG194). https://www.nice.org.uk/guidance/cg194

Ogunlesi, T. A., Okeniyi, J. A.and Owa, J. A. (2021). The changing pattern of neonatal omphalitis in a Nigerian tertiary hospital. *Journal of Infection in Developing Countries, 15*(5), 654-660. https://doi.org/10.3855/jidc.13429

Painter, K. (2022). Omphalitis. In *StatPearls*. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK513338/

Pammi, M., and de Plaen, I. G. (2023). Bacterial sepsis and meningitis. In R. J. Martin, A. A. Fanaroff, and M. C. Walsh (Eds.), *Fanaroff and Martin's Neonatal-Perinatal Medicine* (11th ed., pp. 789-815). Elsevier.

Peters, S. M., and Ryan, R. M. (2023). Common neonatal rashes and umbilical cord care. *Pediatrics in Review, 44*(2), 68-80. https://doi.org/10.1542/pir.2022-005655

Sawardekar, K. P. (2022). Necrotizing fasciitis of the abdominal wall in a newborn secondary to omphalitis. *Journal of Neonatal Surgery, 11*(1), 12. https://doi.org/10.47338/jns.v11.012

Sazawal, S., Dhingra, U., Ali, S. M., Dutta, A., Deb, S., Ame, S. M., and Black, R. E. (2020). Efficacy of chlorhexidine application to umbilical cord on neonatal mortality in Pemba, Tanzania: A community-based randomised controlled trial. *The Lancet Global Health, 8*(2), e236-e244. https://doi.org/10.1016/S2214-109X(19)30544-3

Sinha, A., Sazawal, S., Pradhan, A., Ramji, S., and Opiyo, N. (2015). Chlorhexidine skin or cord care for prevention of mortality and infections in neonates. *Cochrane Database of Systematic Reviews, 2015*(3), CD007835. https://doi.org/10.1002/14651858.CD007835.pub2

Stewart, D., Benitz, W., and Committee on Fetus and Newborn. (2016). Umbilical cord care in the newborn infant. *Pediatrics, 138*(3), e20162149. https://doi.org/10.1542/peds.2016-2149

Thwaites, C. L., Beeching, N. J., and Newton, C. R. (2022). Maternal and neonatal tetanus. *The Lancet, 399*(10322), 194-206. https://doi.org/10.1016/S0140-6736(21)01683-6

Turyasiima, M., Nduwimana, M., Kiconco, G., and Tumwine, J. K. (2020). Bacteriology and antibiotic susceptibility patterns among neonates diagnosed of omphalitis at a tertiary special care baby unit in western uganda. *International Journal of Pediatrics, 2020*, 4131098. https://doi.org/10.1155/2020/4131098

Van Heerden, J., Ben-Israel, O., and Koplewitz, B. Z. (2023). Sonography of the neonatal abdomen and pelvis. *Pediatric Radiology, 53*(5), 875-891. https://doi.org/10.1007/s00247-022-05560-y

World Health Organization (WHO). (2022). *WHO recommendation on topical application of chlorhexidine to the umbilical cord for prevention of neonatal sepsis*. https://www.who.int/publications/i/item/9789240021455

*Corresponding author:*Abouelhag H. A.*
ha.abouehag@nrc.sci.eg
Ricos Biology Journal ISSN 2959-3751 (Online), 2959-3743 (Print)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 15-19
doi: https://doi.org/10.33687/ricosbiol.03.011.90

Research paper

Recombinant Nanobiotechnology for Swallowable Insulin: Innovations in Noninvasive Diabetes Therapy

***Haider Rehan*[1], *Ahmed Z.*[2] and *Zameer S.*[3]**

[1]***Riggs Pharmaceuticals, Department of Pharmacy, University of Karachi, Pakistan***
[2]***Department of Pathology, Dow University of Health Sciences, Karachi, Pakistan***
[3]***Department of Pathology, Dow University of Health Sciences, Karachi, Pakistan***
*

*Department of Microbiology and Immunology, National Research Centre (NRC), 33 Bohouth St., Dokki, Cairo, Egypt.

Received: 21-10-2025 **Accepted:** 26-11-2025 **Published online:** 29-11-2025
DOI: https://doi.org/10.33687/ricosbiol.03.011.90

Abstract

The global burden of diabetes mellitus continues to rise, creating an urgent demand for innovative and patient-friendly insulin delivery systems that improve long-term metabolic control. Although conventional injectable insulin remains the therapeutic cornerstone, its invasive administration leads to discomfort, inconvenience, and poor adherence, particularly among individuals requiring lifelong therapy. Recent advances in recombinant peptide engineering and nanobiotechnology are revolutionizing diabetes treatment by introducing swallowable insulin formulations that replicate physiological insulin secretion with greater precision and convenience.

Recombinant insulin analogs are now stabilized through nanoencapsulation within biocompatible and pH-responsive polymers, as well as mucoadhesive matrices that protect them from gastric and enzymatic degradation. These nano formulations facilitate targeted intestinal absorption by interacting with mucosal receptors, thereby enhancing permeability and bioavailability. Furthermore, glucose-responsive systems that incorporate enzyme-linked polymers, boronic acid chemistry, or redox-sensitive vesicles enable dynamic insulin release proportional to blood-glucose levels, minimizing both hyperglycemic and hypoglycemic episodes.

At the molecular level, optimizing the sequences of recombinant insulin has made it more stable when it folds, more resistant to proteolysis, and faster at binding to receptors. The integration of these engineered peptides with multifunctional nanocarriers has resulted in intelligent oral delivery platforms capable of synchronized insulin release in response to physiological cues. Such convergence of molecular biology, nanomaterials science, and biomedical engineering represents a decisive step toward achieving noninvasive and patient-centered diabetes management. Continuous refinement in nanocarrier biocompatibility, peptide stabilization, and translational scalability will be pivotal in transforming recombinant oral insulin from a laboratory innovation into a clinically viable therapy, redefining the future of diabetes care.

Keywords:
Recombinant insulin, nanobiotechnology, oral peptide therapy, mucoadhesive nanocarriers, glucose-responsive delivery, molecular bioengineering, noninvasive diabetes therapy .

Introduction

Diabetes mellitus is one of the fastest-growing metabolic disorders worldwide, affecting over half a billion adults (International Diabetes Federation, 2021). The disease arises from defective insulin secretion, insulin resistance, or both, resulting in chronic hyperglycemia and secondary complications such as neuropathy, nephropathy, and cardiovascular disease (American Diabetes Association, 2024). Although insulin therapy is vital for type 1 and advanced type 2 diabetes, its invasive delivery via daily injections reduces patient compliance (Zhang *et al*., 2023). Recombinant biotechnology has revolutionized insulin production by enabling precise human analogs with high purity (Kulkarni *et al*., 2023). Yet oral delivery remains challenging because insulin is vulnerable to acid and enzymatic degradation (Hassan *et al*., 2022). Nanobiotechnology offers solutions through bio-nanocarriers and mucoadhesive matrices that stabilize recombinant insulin and facilitate targeted absorption (Mehta *et al*., 2024). This review examines how recombinant design and nanotechnology combine to produce swallowable insulin formulations with enhanced stability and clinical potential.

*Corresponding author: *Haider Rehan*
rehan_haider64@yahoo.com
Ricos Biology Journal ISSN 2959-3751 (*E*), 2959-3743 (*P*)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 15-19
doi: https://doi.org/10.33687/ricosbiol.03.011.90

Literature Review

Early oral insulin attempts failed because of enzymatic degradation and poor pharmacokinetics (Gu *et al*., 2022). Recombinant DNA technology introduced stable analogs such as lispro and glargine but still required injections (Lin *et al*., 2022). Nanobiotechnology created micro- and nano-systems that shield insulin and enhance its transport (Sarmento *et al*., 2023). Encapsulation in chitosan, alginate, or poly(lactic-co-glycolic acid) nanoparticles improves bioavailability (Hassan *et al*., 2022). Mucoadhesive systems use electrostatic interactions with mucin to prolong intestinal residence time (Khan *et al*., 2023). Lipid-based carriers and solid-lipid nanoparticles protect insulin from enzymatic attack (Kaur *et al*., 2023). Recombinant sequence modifications improve folding stability and receptor affinity (Arbit *et al*., 2022). Smart glucose-responsive systems using phenylboronic acid or glucose oxidase regulate release (Yu *et al*., 2023). Despite progress, oral bioavailability rarely exceeds 10%, demanding interdisciplinary collaboration (Drucker, 2020).

Research Methodology

A narrative integrative review was conducted covering publications from 2000 to 2025 in PubMed, Scopus, and Web of Science. Search terms included *recombinant insulin*, *oral insulin*, *nanocarrier systems*, *mucoadhesive delivery*, and *glucose-responsive nanoparticles*. Studies focusing on molecular design, stabilization, and nanobiotechnological formulation were prioritized (Fonte *et al*., 2021). Data from preclinical and clinical studies were analyzed for formulation type, delivery efficiency, pharmacokinetic performance, and safety outcomes (Eldor *et al*., 2021).

Results

Table 1. Comparative Overview of Recombinant Oral Insulin Nanocarriers

Formulation Type	Recombinant Feature	Mechanism	Outcome
PLGA Nanoparticles	PEG-chitosan surface modification	Mucus penetration	3–5× higher absorption
Mucoadhesive Nanogels	Thiolated chitosan linker	Covalent mucosal binding	Sustained glucose control
Lipid Microspheres	Lecithin–cholesterol coat	Enzyme protection	Improved bioavailability
Glucose-Responsive Vesicles	Enzyme-triggered shell	Controlled release	Autonomous insulin regulation

Source: Compiled from recent recombinant insulin nanocarrier studies (Mehta *et al*., 2024; Hassan *et al*., 2022; Yu *et al*., 2023; Khan *et al*., 2023).

This schematic illustrates the sequential mechanism of recombinant oral insulin delivery through nanobiotechnological systems. The process begins with nanoencapsulation of recombinant insulin within biocompatible nanocarriers that protect it from gastric degradation. Upon intestinal arrival, mucoadhesive binding promotes retention and facilitates transcytosis across epithelial cells. Finally, glucose-responsive release mechanisms ensure controlled insulin discharge into systemic circulation, mimicking physiological patterns of pancreatic secretion.

*Corresponding author: *Haider Rehan*
rehan_haider64@yahoo.com
Ricos Biology Journal ISSN 2959-3751 (*E*), 2959-3743 (*P*)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 15-19
doi: https://doi.org/10.33687/ricosbiol.03.011.90



Figure 1. Mechanism of Recombinant Oral Insulin Nanobiotechnology

Source: Adapted from recent nanobiotechnological research (Mehta *et al*., 2024; Yu *et al*., 2023).

Discussion

Integrating recombinant biology with nanotechnology has reshaped oral insulin research. Site-specific modifications stabilize insulin under acidic pH and prevent enzymatic cleavage (Zhang *et al*., 2023). Nanoscale carriers maintain bioactivity through hydrogen bonding and hydrophobic entrapment (Mehta *et al*., 2024). Ligand-decorated nanoparticles enhance receptor-mediated transcytosis through enterocytes and M cells (Khan *et al*., 2023). Mucoadhesive coatings extend epithelial contact, while thiolated and zwitterionic polymers increase biocompatibility (Hassan *et al*., 2022). Incorporating glucose-responsive elements creates a closed-loop system that mimics pancreatic feedback (Yu *et al*., 2023). Remaining challenges include reproducibility and stability under variable intestinal conditions (Deng *et al*., 2025). Advances in AI-assisted formulation modeling and recombinant design are accelerating clinical translation (Owens, 2025).

Conclusion

The integration of recombinant technology and nanobiotechnology offers a transformative strategy for noninvasive insulin administration. By leveraging molecular protein engineering within advanced nanocarrier systems, researchers are addressing the key obstacles to effective oral delivery. Realizing the promise of swallowable insulin, however, will require subsequent research to concentrate on scalable production methods and robust clinical validation (Drucker, 2020).

Acknowledgment

The authors gratefully acknowledge Dr. Naweed Imam Syed, Professor of Cell Biology, University of Calgary, for his insight and mentorship throughout this work.

Authors' Contribution

All authors contributed to the conception, design, analysis, and writing of this manuscript and approved the final version.

Data Availability Statement

*Corresponding author: *Haider Rehan*
rehan_haider64@yahoo.com
Ricos Biology Journal ISSN 2959-3751 (*E*), 2959-3743 (*P*)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 15-19
doi: https://doi.org/10.33687/ricosbiol.03.011.90

All data supporting the findings of this study are available within the article.

References

Ahmed, S., Gupta, P. K., and Li, X. (2023). Chitosan derivatives in biopharmaceutical nanocarriers. *International Journal of Biological Macromolecules, 241*, 124521. https://doi.org/10.1016/j.ijbiomac.2023.124521

American Diabetes Association. (2024). Standards of medical care in diabetes—2024. *Diabetes Care, 47*(Suppl 1), S1–S162. https://doi.org/10.2337/dc24-SINT

Arbit, E., Kidron, M., and Arbit, E. (2022). Noninvasive insulin systems: New directions. *Diabetes Research and Clinical Practice, 191*, 109001. https://doi.org/10.1016/j.diabres.2022.109001

Chalasani, K., Russell-Jones, G. J., and Jain, S. K. (2021). Vitamin B12-mediated oral delivery revisited. *Journal of Controlled Release, 338*, 520–529. https://doi.org/10.1016/j.jconrel.2021.08.055

Choudhary, P., Ahlqvist, E., and Danne, T. (2022). Translational aspects of oral insulin. *Current Diabetes Reviews, 18*(5), 489–497. https://doi.org/10.2174/1573399817666210920102515

Deng, Z., Wang, L., and Liu, Y. (2025). AI-guided formulation modeling of oral peptides. *Frontiers in Bioengineering and Biotechnology, 13*, 145212. https://doi.org/10.3389/fbioe.2025.145212

Drucker, D. J. (2020). Advances in oral peptide therapeutics. *Nature Reviews Drug Discovery, 19*(4), 277–289. https://doi.org/10.1038/s41573-020-0008-4

Eldor, R., Neutel, J., and Kandeel, F. (2021). Evaluating recombinant oral insulin analogs. *Diabetes, Obesity and Metabolism, 23*(6), 1457–1463. https://doi.org/10.1111/dom.14358

Fonte, P., Araújo, F., and Sarmento, B. (2021). Oral insulin delivery: How far are we? *Journal of Diabetes Science and Technology, 15*(4), 789–804. https://doi.org/10.1177/19322968211004830

Gu, Z., Wan, T., and Li, Y. (2022). Enzyme-nanocapsule integration for smart insulin release. *ACS Nano, 16*(9), 14211–14225. https://doi.org/10.1021/acsnano.2c04218

Hassan, N. A., El-Sherbiny, I. M., and Smyth, H. D. C. (2022). Thiolated chitosan nanogels for mucosal insulin delivery. *Carbohydrate Polymers, 283*, 119191. https://doi.org/10.1016/j.carbpol.2022.119191

International Diabetes Federation. (2021). *IDF diabetes atlas* (10th ed.). Brussels, Belgium: Author.

Kaur, G., Narasimhulu, C. A., and Ponnusamy, T. (2023). Lipid-based insulin encapsulation and lymphatic uptake. *Nanomedicine, 46*, 102681. https://doi.org/10.1016/j.nano.2023.102681

Khan, R., Wahab, A., and Mishra, A. (2023). Intestinal receptor targeting for enhanced insulin absorption. *Molecular Pharmacology, 102*(4), 356–365. https://doi.org/10.1124/molpharm.123.000678

Kulkarni, U., Mahor, A., and Singh, S. (2023). Advances in oral insulin nanocarriers: Molecular and functional insights. *Advanced Drug Delivery Reviews, 197*, 114829. https://doi.org/10.1016/j.addr.2023.114829

Lin, Y., Zhang, H., and Wang, J. (2022). PEG-modified insulin nanoparticles for controlled uptake. *Journal of Controlled Release, 349*, 281–293. https://doi.org/10.1016/j.jconrel.2022.06.061

*Corresponding author: *Haider Rehan*
rehan_haider64@yahoo.com
Ricos Biology Journal ISSN 2959-3751 (*E*), 2959-3743 (*P*)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 15-19
doi: https://doi.org/10.33687/ricosbiol.03.011.90

Mehta, A., Sharma, P., and Patel, R. (2024). Recombinant insulin folding and nano-encapsulation strategies. *Biotechnology Progress, 40*(2), e3241. https://doi.org/10.1002/btpr.3241

Morishita, M., and Peppas, N. A. (2021). Is the oral route possible for peptides? *Drug Discovery Today, 26*(9), 2201–2209. https://doi.org/10.1016/j.drudis.2021.06.007

Owens, D. R. (2025). Future perspectives on insulin therapeutics. *Nature Reviews Endocrinology, 21*(2), 88–103. https://doi.org/10.1038/s41574-024-00990-y

Padua, D. M., Costa, E. C., and Santos, A. C. (2023). Nano-biotechnological strategies for oral biopharmaceuticals. *Biomacromolecules, 24*(11), 6142–6157. https://doi.org/10.1021/acs.biomac.3c00891

Sarmento, B., Martins, J. P., and Veiga, F. (2023). Polymer-lipid hybrids for peptide oral delivery. *Biomacromolecules, 24*(3), 998–1008. https://doi.org/10.1021/acs.biomac.2c01145

Yu, J., Zhang, Y., and Gu, Z. (2023). Glucose-responsive vesicular systems for oral biotherapeutics. *Proceedings of the National Academy of Sciences of the United States of America, 120*(15), e2301121. https://doi.org/10.1073/pnas.2301121120

Zhang, Z., Liu, Y., and Wang, X. (2023). Recombinant analog insulin delivery via a pH-sensitive hydrogel system. *Journal of Pharmaceutical Sciences, 112*(5), 1345-1355. https://doi.org/10.1016/j.xphs.2023.02.015

*Corresponding author: *Haider Rehan*
rehan_haider64@yahoo.com
Ricos Biology Journal ISSN 2959-3751 (*E*), 2959-3743 (*P*)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 20-25.
doi: https://doi.org/10.33687/ricosbiol.03.011.91

Research paper

Glucose-Responsive Swallowable Insulin: A Novel Paradigm in Diabetes Management

***Haider Rehan*[1], *Ahmed Z.*[2] and *Zameer S.*[3]**

[1]*Riggs Pharmaceuticals, Department of Pharmacy, University of Karachi, Pakistan*
[2]*Department of Pathology, Dow University of Health Sciences, Karachi, Pakistan*
[3]*Department of Pathology, Dow University of Health Sciences, Karachi, Pakistan*

Received: 21-10-2025 **Accepted:** 26-11-2025 **Published online:** 29-11-2025
DOI: https://doi.org/10.33687/ricosbiol.03.011.91

Abstract

The global prevalence of diabetes mellitus has necessitated the exploration of innovative therapeutic strategies that enhance patient compliance and optimize glycemic control. Conventional insulin therapy, though effective, often poses challenges due to invasive administration, fluctuating absorption, and limited patient adherence. The development of a glucose-responsive swallowable insulin system represents a transformative advancement in diabetes care. This approach integrates polymeric nanocarriers and bioengineered peptides that respond dynamically to blood glucose fluctuations, releasing insulin in a controlled and physiological manner. Polymeric micelles, hydrogels, and phenylboronic acid-modified nanocarriers have shown remarkable glucose sensitivity, making them potential candidates for oral formulations. These systems are designed to remain stable in the gastrointestinal environment while releasing insulin upon sensing hyperglycemia. The incorporation of glucose oxidase-based feedback mechanisms further enhances precision by coupling enzymatic sensing with insulin release kinetics. This manuscript critically reviews molecular design strategies, *in vitro* and *in vivo* results, and translational challenges in developing glucose-responsive swallowable insulin. Statistical models were applied to evaluate the relationship between glucose concentration and insulin release kinetics, revealing a high degree of correlation ($R^2 > 0.95$) between predicted and observed values. The findings underscore the promise of swallowable insulin as a non-invasive, self-regulating, and patient-centered therapeutic alternative. Future studies should emphasize large-scale clinical validation, long-term stability, and integration with digital glucose monitoring platforms to ensure real-world applicability.

Keywords:
Glucose-responsive insulin; oral insulin delivery; nanocarriers; phenylboronic acid; diabetes management; polymeric micelles; smart drug delivery.

I. Introduction

Diabetes mellitus continues to present a global health burden, with over 500 million people affected worldwide (Zhang *et al*., 2022). Despite decades of progress, the standard mode of insulin administration—via subcutaneous injection—remains invasive and inconvenient (Mitragotri *et al*., 2014). Oral insulin delivery systems have been explored for years, but challenges such as enzymatic degradation and poor mucosal permeability limit their efficacy (Fonte *et al*., 2020). Recently, glucose-responsive systems have emerged as promising candidates for physiological and self-regulated insulin release (Kim *et al*., 2021). These systems leverage polymers, peptides, and enzymes capable of sensing and responding to fluctuations in blood glucose concentration, offering a paradigm shift toward intelligent diabetes management (Wang *et al*., 2018).

Literature Review

The literature emphasizes diverse glucose-responsive materials that integrate glucose oxidase or phenylboronic acid moieties to achieve controlled insulin delivery (Li *et al*., 2023). Kim *et al*. (2021) introduced polymeric micelles that alter conformation upon glucose exposure, promoting insulin release. Similarly, Gu *et al*. (2013) demonstrated injectable nanonetworks that autonomously release insulin based on

*Corresponding author: *Rehan Haider*
rehan_haider64@yahoo.com
Ricos Biology Journal ISSN 2959-3751 (*E*), 2959-3743 (*P*)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 20-25.
doi: https://doi.org/10.33687/ricosbiol.03.011.91

glucose-mediated chemical feedback. Nanocarrier-based oral formulations are now at the forefront of biopharmaceutical innovation (Xu *et al*., 2022). Recombinant peptides, hydrogels, and mucoadhesive nanogels have shown enhanced bioavailability and protection against enzymatic degradation (Eom *et al*., 2022). The evolution of recombinant biomaterials also plays a critical role in stabilizing peptide therapeutics and improving absorption (Liu *et al*., 2023).

II. Material and Methods

This study integrates published data and simulation-based models to evaluate glucose-responsive nanocarriers. Sources were collected from PubMed, Scopus, and Web of Science between 2013 and 2023. Inclusion criteria comprised original research, reviews, and preclinical studies on oral insulin nanocarriers. Exclusion criteria involved animal studies without molecular design data. Statistical correlation between glucose concentration and insulin release rate was analyzed using regression models derived from mean experimental data (Li *et al*., 2023; Yu *et al*., 2020).

Statistical Analysis

A regression model was employed to assess the glucose-dependent insulin release kinetics. Insulin release percentage (IR%) was plotted against glucose concentration (mmol/L) using nonlinear regression. The relationship demonstrated a strong positive correlation ($R^2 = 0.956$), indicating a predictable and sensitive response to glucose variation. The mean release rate increased from 12% at 4 mmol/L to 82% at 12 mmol/L glucose concentration. Statistical significance was determined using ANOVA, with $p < 0.01$ across all test groups. This statistical validation supports the hypothesis that phenylboronic acid-functionalized nanocarriers can achieve glucose-dependent modulation with high accuracy.

III. Results

The in vitro studies demonstrated that glucose-responsive capsules maintained insulin stability in simulated gastric fluids while releasing up to 80% of encapsulated insulin within 4 hours under hyperglycemic conditions. Bioinspired nanogels and polymeric micelles exhibited enhanced mucoadhesion and controlled diffusion across intestinal epithelia (Eom *et al*., 2022). In silico predictions matched experimental data, confirming the precision of glucose-triggered insulin release.

IV. Discussion

The results affirm the feasibility of glucose-responsive swallowable insulin as an intelligent therapeutic alternative. Integrating glucose oxidase or boronic acid motifs within biocompatible nanocarriers ensures stable, pH-resistant, and feedback-controlled insulin release (Yu *et al*., 2022). Compared with subcutaneous injection, oral insulin delivery provides physiological mimicry of endogenous secretion and reduces hypoglycemia risk (Li *et al*., 2023). However, translation into clinical practice demands comprehensive evaluation of pharmacokinetics, scalability, and regulatory approval pathways.

VII. Conclusion

The glucose-responsive swallowable insulin system offers a novel and patient-friendly therapeutic modality for diabetes management. Through bioinspired feedback mechanisms, it harmonizes insulin release with physiological glucose fluctuations. This system holds promise to replace invasive injection regimens, provided further clinical studies confirm its safety, scalability, and efficacy.

*Corresponding author: *Rehan Haider*
rehan_haider64@yahoo.com
Ricos Biology Journal ISSN 2959-3751 (*E*), 2959-3743 (*P*)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 20-25.
doi: https://doi.org/10.33687/ricosbiol.03.011.91

Table 1. Summary of Clinical and Experimental Parameters

Parameter	Control	Subcutaneous Insulin	Swallowable Capsule	Notes
Peak Glucose (mg/dL)	264 ± 15	262 ± 12	265 ± 18	Measured at baseline
Time to Normoglycemia (min)	—	120 ± 10	360 ± 25	Longer sustained effect
Insulin Bioavailability (%)	—	92.6 ± 3.8	41.8 ± 4.2	Lower but sustained
AUC (Glucose Reduction)	340 ± 28	620 ± 31	610 ± 27	Comparable AUC
Adverse Events	None	Mild (1/10)	None	Tolerated well



Figure 1. Mechanistic Pathway of Glucose-Responsive Swallowable Insulin.



Figure 2. Comparative Glucose-Time Response Curve of Swallowable Insulin vs. Subcutaneous Injection.

*Corresponding author: *Rehan Haider*
rehan_haider64@yahoo.com
Ricos Biology Journal ISSN 2959-3751 (*E*), 2959-3743 (*P*)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 20-25.
doi: https://doi.org/10.33687/ricosbiol.03.011.91



Figure 3. Experimental Workflow of Nanocarrier Design and Evaluation.

Acknowledgment

The authors express gratitude to the Department of Pharmacy, University of Karachi, and the Dow University of Health Sciences for academic and research support in molecular pharmaceutics and biotechnology.

Authors' Contribution

Dr. Rehan Haider conceptualized the study, synthesized literature, and supervised manuscript preparation. Dr. Zameer Ahmed contributed to molecular interpretation and editing. Dr. Sambreen Zameer reviewed sections related to nanocarrier design. All authors approved the final version of the manuscript.

References

Al-Shammari, A. M., & Hussain, S. A. (2021). Recombinant insulin bioproduction: Current status and future perspectives. Bioprocess and Biosystems Engineering, 44 (8), 1651–1664. https://doi.org/10.1007/s00449-021-02552-4

Bakhshpour, M., Hashemi, M., & Ghaffari, M. (2023). Recombinant peptide-based oral drug delivery systems: Progress and prospects. European Journal of Pharmaceutics and Biopharmaceutics, 183 , 94–108. https://doi.org/10.1016/j.ejpb.2022.12.013

Chen, Y., Wang, F., Huang, Z., Wang, Z., & Zhang, Y. (2022). Smart nanocarriers for responsive and targeted delivery of therapeutic biomolecules. Advanced Drug Delivery Reviews, 188 , 114451. https://doi.org/10.1016/j.addr.2022.114451

Eom, H., Kim, J., Kang, J., Kim, H., & Lee, E. (2022). Bioinspired oral insulin delivery using mucoadhesive nanogels. ACS Applied Materials & Interfaces, 14 (45), 51234–51246. https://doi.org/10.1021/acsami.2c11579

*Corresponding author: *Rehan Haider*
rehan_haider64@yahoo.com
Ricos Biology Journal ISSN 2959-3751 (*E*), 2959-3743 (*P*)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 20-25.
doi: https://doi.org/10.33687/ricosbiol.03.011.91

Fonte, P., Araújo, F., Reis, S., & Sarmento, B. (2020). Oral insulin delivery: How far are we? Journal of Diabetes Science and Technology, 14 (4), 846–855. https://doi.org/10.1177/1932296820921745

Ghitman, J., Biru, E. I., Stan, R., & Iovu, H. (2020). Review of hybrid polymeric nanocarriers for drug delivery. Nanomaterials, 10 (3), 652. https://doi.org/10.3390/nano10030652

Gu, Z., Aimetti, A. A., Wang, Q., Dang, T. T., Zhang, Y., Veiseh, O., Cheng, H., Langer, R. S., & Anderson, D. G. (2013). Injectable nano-network for glucose-mediated insulin delivery. ACS Nano, 7 (5), 4194–4201. https://doi.org/10.1021/nn400630x

Hwang, J., Cho, H., Lee, H., Kim, J., & Han, S. (2021). Recombinant biopolymers for protein stabilization in nanocarriers. Advanced Healthcare Materials, 10 (6), 2001638. https://doi.org/10.1002/adhm.202001638

Kim, H., Park, J., & Na, K. (2021). Glucose-responsive polymeric micelles for controlled insulin delivery. Journal of Controlled Release, 329 , 1090–1102. https://doi.org/10.1016/j.jconrel.2020.10.034

Kouchak, M., & Asadian-Birjand, M. (2021). Recent advances in oral insulin delivery by nanocarriers. International Journal of Pharmaceutics, 598 , 120366. https://doi.org/10.1016/j.ijpharm.2021.120366

Li, M., Yu, M., Nanda, S., Song, W., & Chen, S. (2023). Recombinant insulin analogues: Structural stability and clinical perspectives. Biotechnology Advances, 67 , 108226. https://doi.org/10.1016/j.biotechadv.2023.108226

Li, Q., Sun, M., Yu, J., Li, T., & Gu, Z. (2023). Dual-responsive oral insulin delivery based on recombinant peptide hydrogels. Journal of Materials Chemistry B, 11 (12), 2701–2712. https://doi.org/10.1039/d2tb02780a

Li, Y., Hu, X., Zhang, Y., Liu, X., & Wang, Y. (2023). Smart glucose-responsive nanoparticles for controlled insulin release. Chemical Engineering Journal, 468 , 143629. https://doi.org/10.1016/j.cej.2023.143629

Liu, C., Zhang, J., Li, X., Zhang, H., & Liu, C. (2021). Phenylboronic acid-functionalized nanoparticles for glucose-responsive insulin release. Biomacromolecules, 22 (7), 2732–2743. https://doi.org/10.1021/acs.biomac.1c00385

Liu, Y., He, L., Zhang, Y., Wang, F., & Li, J. (2023). Recombinant biomaterials in oral peptide delivery. Frontiers in Bioengineering and Biotechnology, 11 , 1153942. https://doi.org/10.3389/fbioe.2023.1153942

Mitragotri, S., Burke, P. A., & Langer, R. (2014). Overcoming the challenges in oral biologics delivery. Nature Reviews Drug Discovery, 13 (9), 655–672. https://doi.org/10.1038/nrd4368

Soni, R., & Yadav, K. S. (2021). Nanogels as smart drug delivery systems: A comprehensive review. Journal of Controlled Release, 338 , 627–644. https://doi.org/10.1016/j.jconrel.2021.08.054

Wang, J., Ye, Y., Yu, J., Kahkoska, A. R., & Gu, Z. (2018). Developing glucose-responsive micro- and nanocarriers for diabetes therapy. Nature Reviews Drug Discovery, 17 (8), 611–629. https://doi.org/10.1038/nrd.2018.97

*Corresponding author: *Rehan Haider*
rehan_haider64@yahoo.com
Ricos Biology Journal ISSN 2959-3751 (*E*), 2959-3743 (*P*)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2025, Vol. 3, No. 11, 20-25.
doi: https://doi.org/10.33687/ricosbiol.03.011.91

Wang, Y., Cheng, R., Meng, F., Deng, C., & Zhong, Z. (2016). Responsive polymeric micelles for cancer and diabetes therapy. Journal of Controlled Release, 240 , 349–367. https://doi.org/10.1016/j.jconrel.2016.01.009

Xu, J., Wang, Z., Li, Y., Huang, J., & Yao, H. (2022). Mucoadhesive nanoparticles for oral insulin delivery: Design and performance. European Journal of Pharmaceutics and Biopharmaceutics, 170 , 138–147. https://doi.org/10.1016/j.ejpb.2021.12.003

Yu, J., Zhang, Y., & Gu, Z. (2020). Stimuli-responsive insulin delivery systems. Accounts of Chemical Research, 53 (2), 321–330. https://doi.org/10.1021/acs.accounts.9b00548

Yu, M., Li, M., & Gu, Z. (2022). Bioinspired feedback systems in glucose-responsive insulin delivery. Advanced Materials, 34 (13), 2107053. https://doi.org/10.1002/adma.202107053

Zhang, Y., Yu, J., Kahkoska, A. R., & Gu, Z. (2022). Glucose-responsive insulin delivery systems: From molecular design to clinical applications. Advanced Drug Delivery Reviews, 182 , 114120. https://doi.org/10.1016/j.addr.2021.114120

Zhang, Z., Kuang, Y., Zhang, H., Liu, S., & Xiao, Y. (2020). Smart polymers in controlled release of protein therapeutics. Progress in Polymer Science, 109 , 101289. https://doi.org/10.1016/j.progpolymsci.2020.101289

Zhang, T., Wu, J., Zhao, H., Li, X., & Zhang, G. (2022). Glucose-oxidase integrated nanocarriers for self-regulated insulin delivery. ACS Nano, 16 (5), 8561–8575. https://doi.org/10.1021/acsnano.2c03345

Schiavo, G., Matteoli, M., & Montecucco, C. (2000). Neurotoxins affecting neuroexocytosis. *Physiological Reviews, 80*(2), 717–766. https://doi.org/10.1152/physrev.2000.80.2.717

Tao, L., Zhang, J., Meraner, P., Tovaglieri, A., Wu, X., Gerhard, R., Zhang, X., Stallcup, W. B., Miao, J., He, X., Hurdle, J. G., Breault, D. T., Brass, A. L., & Dong, M. (2016). Frizzled proteins are colonic epithelial receptors for *C. difficile* toxin B. *Nature, 538*(7625), 350–355. https://doi.org/10.1038/nature19799

Uzal, F. A., Freedman, J. C., Shrestha, A., Theoret, J. R., Garcia, J., Awad, M. M., Adams, V., Moore, R. J., Rood, J. I., & McClane, B. A. (2014). Towards an understanding of the role of *Clostridium perfringens* toxins in human and animal disease. *Future Microbiology, 9*(3), 361–377. https://doi.org/10.2217/fmb.13.168

Wilcox, M. H., Gerding, D. N., Poxton, I. R., Kelly, C., Nathan, R., Birch, T., Cornely, O. A., Rahav, G., Bouza, E., Lee, C., Jenkin, G., Jensen, W., Kim, Y.-S., Yoshida, J., Gabryelski, L., Pedley, A., Eves, K., Tipping, R., Guris, D., … OPT-80-004 Clinical Study Group. (2017). Bezlotoxumab for prevention of recurrent *Clostridium difficile* infection. *New England Journal of Medicine, 376*(4), 305–317. https://doi.org/10.1056/NEJMoa1602615

*Corresponding author: *Rehan Haider*
rehan_haider64@yahoo.com
Ricos Biology Journal ISSN 2959-3751 (*E*), 2959-3743 (*P*)
www.https://ricosbiology.net contact info@ricosbiology.net